Conclusions
stroke
STROKE, SECONDARY
In this prespecified secondary analysis of a randomized clinical trial using Medicare billing data to obtain follow-up for up to 23 years after baseline, we found similar results as those found during the ALLHAT. Angiotensin-converting enzyme inhibitors were associated with an increased risk of stroke outcomes (11% increased risk of combined fatal and nonfatal hospitalized stroke) compared with diuretics, and this effect persisted well beyond the trial period.